Physician profile
David J Friedman
NPI 1215931050
$11,087.67
in general payments reported to CMS, 2019-2025
27 companies · $2,340 in 2025
The $2,340 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,801 · 2020: $1,075 · 2021: $1,883 · 2022: $1,665 · 2023: $1,423 · 2024: $902 · 2025: $2,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,439 · Honoraria: $175 · Consulting Fee: $38.44 · Education: $12.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,438.95 |
| Honoraria | $175.00 |
| Consulting Fee | $38.44 |
| Education | $12.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,871.94 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,431.79 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $859.16 | 2019-2025 | Dupixent |
| Genzyme Corporation | $685.19 | 2019-2025 | |
| Optinose US, INC. | $479.70 | 2019-2023 | |
| Genentech USA, INC. | $440.49 | 2019-2025 | Xolair |
| Csl Behring | $426.86 | 2020-2025 | Andembry, Hizentra, Privigen |
| Amgen INC. | $268.27 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $232.09 | 2021-2025 | Cuvitru, Glassia |
| Aimmune Therapeutics, INC. | $212.54 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.90 | 2020-2022 | |
| Grifols USA, LLC | $172.68 | 2020-2023 | Xembify |
| Novartis Pharmaceuticals Corporation | $139.55 | 2019-2023 | |
| Pfizer INC. | $136.41 | 2019-2023 | |
| Pharming Healthcare, INC. | $110.94 | 2025 | Ruconest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $70.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Kaleo, INC. | $62.82 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $43.34 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $38.44 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $33.57 | 2019-2020 | |
| Blueprint Medicines Corporation | $20.76 | 2023 | Ayvakit |
| Phadia US INC. | $17.11 | 2021 | |
| Circassia INC. | $17.10 | 2019 | |
| Hikma Pharmaceuticals USA | $17.02 | 2024 | Ryaltris |
| Shire North American Group INC | $15.48 | 2019 | |
| Tactile Systems Technology INC | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.